{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:03:34Z","timestamp":1768781014678,"version":"3.49.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2011,3,11]],"date-time":"2011-03-11T00:00:00Z","timestamp":1299801600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1007\/s00415-011-5969-1","type":"journal-article","created":{"date-parts":[[2011,3,10]],"date-time":"2011-03-10T13:15:05Z","timestamp":1299762905000},"page":"1497-1506","source":"Crossref","is-referenced-by-count":38,"title":["The health-related, social, and economic consequences of parkinsonism: a controlled national study"],"prefix":"10.1007","volume":"258","author":[{"given":"Poul","family":"Jennum","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marielle","family":"Zoetmulder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lise","family":"Korbo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakob","family":"Kjellberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,3,11]]},"reference":[{"key":"5969_CR1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1136\/jnnp.62.1.10","volume":"62","author":"MC Rijk de","year":"1997","unstructured":"de Rijk MC, Tzourio C, Breteler MM et al (1997) Prevalence of parkinsonism and Parkinson\u2019s disease in Europe: the EUROPARKINSON Collaborative Study European Community Concerted Action on the Epidemiology of Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 62:10\u201315","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"5969_CR2","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1136\/jnnp.2008.162222","volume":"80","author":"MM Wickremaratchi","year":"2009","unstructured":"Wickremaratchi MM, Perera D, O\u2019Loghlen C et al (2009) Prevalence and age of onset of Parkinson\u2019s disease in Cardiff: a community based cross sectional study and meta-analysis. J Neurol Neurosurg Psychiatry 80:805\u2013807","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"5969_CR3","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1159\/000201565","volume":"32","author":"M Yamawaki","year":"2009","unstructured":"Yamawaki M, Kusumi M, Kowa H, Nakashima K (2009) Changes in prevalence and incidence of Parkinson\u2019s disease in Japan during a quarter of a century. Neuroepidemiology 32:263\u2013269","journal-title":"Neuroepidemiology"},{"key":"5969_CR4","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/mds.22359","volume":"24","author":"EJ Newman","year":"2009","unstructured":"Newman EJ, Grosset KA, Grosset DG (2009) Geographical difference in Parkinson\u2019s disease prevalence within West Scotland. Mov Disord 24:401\u2013406","journal-title":"Mov Disord"},{"key":"5969_CR5","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.parkreldis.2008.07.006","volume":"15","author":"KF Pedersen","year":"2009","unstructured":"Pedersen KF, Larsen JP, Alves G, Aarsland D (2009) Prevalence and clinical correlates of apathy in Parkinson\u2019s disease: a community-based study. Parkinsonism Relat Disord 15:295\u2013299","journal-title":"Parkinsonism Relat Disord"},{"key":"5969_CR6","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1212\/01.wnl.0000252807.38124.a3","volume":"68","author":"D Hirtz","year":"2007","unstructured":"Hirtz D, Thurman DJ, Gwinn-Hardy K, Mohamed M, Chaudhuri AR, Zalutsky R (2007) How common are the \u201ccommon\u201d neurologic disorders? Neurology 68:326\u2013337","journal-title":"Neurology"},{"key":"5969_CR7","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1212\/WNL.57.12.2278","volume":"57","author":"M Guttman","year":"2001","unstructured":"Guttman M, Slaughter PM, Theriault ME, DeBoer DP, Naylor CD (2001) Parkinsonism in Ontario: increased mortality compared with controls in a large cohort study. Neurology 57:2278\u20132282","journal-title":"Neurology"},{"key":"5969_CR8","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/0021-9681(73)90105-7","volume":"26","author":"E Singer","year":"1973","unstructured":"Singer E (1973) Social costs of Parkinson\u2019s disease. J Chronic Dis 26:243\u2013254","journal-title":"J Chronic Dis"},{"key":"5969_CR9","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S1353-8020(99)00012-7","volume":"5","author":"C McRae","year":"1999","unstructured":"McRae C, Sherry P, Roper K (1999) Stress and family functioning among caregivers of persons with Parkinson\u2019s disease. Parkinsonism Relat Disord 5:69\u201375","journal-title":"Parkinsonism Relat Disord"},{"key":"5969_CR10","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/BF03324464","volume":"14","author":"M Caap-Ahlgren","year":"2002","unstructured":"Caap-Ahlgren M, Dehlin O (2002) Factors of importance to the caregiver burden experienced by family caregivers of Parkinson\u2019s disease patients. Aging Clin Exp Res 14:371\u2013377","journal-title":"Aging Clin Exp Res"},{"key":"5969_CR11","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2165\/00002512-200623090-00001","volume":"23","author":"CH Dowding","year":"2006","unstructured":"Dowding CH, Shenton CL, Salek SS (2006) A review of the health-related quality of life and economic impact of Parkinson\u2019s disease. Drugs Aging 23:693\u2013721","journal-title":"Drugs Aging"},{"key":"5969_CR12","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1136\/jnnp.69.5.584","volume":"69","author":"KH Karlsen","year":"2000","unstructured":"Karlsen KH, Tandberg E, Arsland D, Larsen JP (2000) Health related quality of life in Parkinson\u2019s disease: a prospective longitudinal study. J Neurol Neurosurg Psychiatry 69:584\u2013589","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"5969_CR13","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1002\/mds.21123","volume":"21","author":"A Korchounov","year":"2006","unstructured":"Korchounov A, Bogomazov G (2006) Employment, medical absenteeism, and disability perception in Parkinson\u2019s disease: a pilot double-blind, randomized, placebo-controlled study of entacapone adjunctive therapy. Mov Disord 21:2220\u20132224","journal-title":"Mov Disord"},{"key":"5969_CR14","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1002\/mds.21030","volume":"21","author":"A Schrag","year":"2006","unstructured":"Schrag A, Banks P (2006) Time of loss of employment in Parkinson\u2019s disease. Mov Disord 21:1839\u20131843","journal-title":"Mov Disord"},{"key":"5969_CR15","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1002\/mds.22414","volume":"24","author":"A Diem-Zangerl","year":"2009","unstructured":"Diem-Zangerl A, Seppi K, Wenning GK, Trinka E, Ransmayr G, Oberaigner W, Poewe W (2009) Mortality in Parkinson\u2019s disease: a 20\u00a0year follow-up study. Mov Disord 24:819\u2013825","journal-title":"Mov Disord"},{"issue":"14","key":"5969_CR16","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1212\/WNL.0b013e3181f61311","volume":"75","author":"EB Forsaa","year":"2010","unstructured":"Forsaa EB, Larsen JP, Wentzel-Larsen T, Alves G (2010) What predicts mortality in Parkinson disease? A prospective population-based long-term study. Neurology 75(14):1270\u20131276","journal-title":"Neurology"},{"key":"5969_CR17","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/ana.21649","volume":"65","author":"EB Montgomery Jr","year":"2009","unstructured":"Montgomery EB Jr (2009) Basal ganglia pathophysiology in Parkinson\u2019s disease. Ann Neurol 65:618 author reply 618\u2013619","journal-title":"Ann Neurol"},{"key":"5969_CR18","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.cortex.2008.11.010","volume":"45","author":"AL Bartels","year":"2009","unstructured":"Bartels AL, Leenders KL (2009) Parkinson\u2019s disease: the syndrome, the pathogenesis and pathophysiology. Cortex 45:915\u2013921","journal-title":"Cortex"},{"key":"5969_CR19","first-page":"S40","volume":"14","author":"D Weintraub","year":"2008","unstructured":"Weintraub D, Comella CL, Horn S (2008) Parkinson\u2019s disease\u2013part 1: pathophysiology, symptoms, burden, diagnosis, and assessment. Am J Manag Care 14:S40\u2013S48","journal-title":"Am J Manag Care"},{"key":"5969_CR20","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1212\/01.wnl.0000252726.13187.63","volume":"67","author":"EB Montgomery Jr","year":"2006","unstructured":"Montgomery EB Jr (2006) Practice parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 67:2266 author reply 2266","journal-title":"Neurology"},{"key":"5969_CR21","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1212\/WNL.0b013e3181a1d44c","volume":"72","author":"CW Olanow","year":"2009","unstructured":"Olanow CW, Stern MB, Sethi K (2009) The scientific and clinical basis for the treatment of Parkinson disease (2009). Neurology 72:S1\u2013S136","journal-title":"Neurology"},{"key":"5969_CR22","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1212\/WNL.0b013e318198e177","volume":"72","author":"AE Lang","year":"2009","unstructured":"Lang AE (2009) When and how should treatment be started in Parkinson disease? Neurology 72:S39\u2013S43","journal-title":"Neurology"},{"key":"5969_CR23","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/WNF.0b013e318065b088","volume":"31","author":"M Stacy","year":"2008","unstructured":"Stacy M, Galbreath A (2008) Optimizing long-term therapy for Parkinson disease: levodopa, dopamine agonists, and treatment-associated dyskinesia. Clin Neuropharmacol 31:51\u201356","journal-title":"Clin Neuropharmacol"},{"key":"5969_CR24","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/WNF.0b013e318065b09c","volume":"31","author":"M Stacy","year":"2008","unstructured":"Stacy M, Galbreath A (2008) Optimizing long-term therapy for Parkinson disease: options for treatment-associated dyskinesia. Clin Neuropharmacol 31:120\u2013125","journal-title":"Clin Neuropharmacol"},{"key":"5969_CR25","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s00702-002-0808-2","volume":"110","author":"H Braak","year":"2003","unstructured":"Braak H, Rub U, Gai WP, Del Tredici K (2003) Idiopathic Parkinson\u2019s disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm 110:517\u2013536","journal-title":"J Neural Transm"},{"key":"5969_CR26","doi-asserted-by":"crossref","first-page":"S332","DOI":"10.1016\/S1353-8020(08)70026-9","volume":"13","author":"EC Hirsch","year":"2007","unstructured":"Hirsch EC (2007) How to improve neuroprotection in Parkinson\u2019s disease? Parkinsonism Relat Disord 13:S332\u2013S335","journal-title":"Parkinsonism Relat Disord"},{"issue":"Suppl","key":"5969_CR27","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/j.parkreldis.2007.06.003","volume":"13","author":"LJ Findley","year":"2007","unstructured":"Findley LJ (2007) The economic impact of Parkinson\u2019s disease. Parkinsonism Relat Disord 13(Suppl):S8\u2013S12","journal-title":"Parkinsonism Relat Disord"},{"key":"5969_CR28","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1136\/jnnp.2005.077677","volume":"77","author":"V Fraix","year":"2006","unstructured":"Fraix V, Houeto JL, Lagrange C et al (2006) Clinical and economic results of bilateral subthalamic nucleus stimulation in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 77:443\u2013449","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"5969_CR29","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1345\/aph.16353","volume":"32","author":"AG Hempel","year":"1998","unstructured":"Hempel AG, Wagner ML, Maaty MA, Sage JI (1998) Pharmacoeconomic analysis of using Sinemet CR over standard Sinemet in parkinsonian patients with motor fluctuations. Ann Pharmacother 32:878\u2013883","journal-title":"Ann Pharmacother"},{"issue":"Suppl 1","key":"5969_CR30","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1007\/s10198-005-0290-5","volume":"5","author":"P Lindgren","year":"2004","unstructured":"Lindgren P (2004) Economic evidence in Parkinson\u2019s disease: a review. Eur J Health Econ 5(Suppl 1):S63\u2013S66","journal-title":"Eur J Health Econ"},{"key":"5969_CR31","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1177\/0272989X04268960","volume":"24","author":"K Noyes","year":"2004","unstructured":"Noyes K, Dick AW, Holloway RG (2004) Pramipexole v levodopa as initial treatment for Parkinson\u2019s disease: a randomized clinical-economic trial. Med Decis Making 24:472\u2013485","journal-title":"Med Decis Making"},{"key":"5969_CR32","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1002\/mds.20999","volume":"21","author":"G Wang","year":"2006","unstructured":"Wang G, Cheng Q, Zheng R et al (2006) Economic burden of Parkinson\u2019s disease in a developing country: a retrospective cost analysis in Shanghai, China. Mov Disord 21:1439\u20131443","journal-title":"Mov Disord"},{"key":"5969_CR33","doi-asserted-by":"crossref","DOI":"10.1201\/9780429246593","volume-title":"An introduction to the bootstrap: (monographs on statistics and applied probablity)","author":"B Efron","year":"1994","unstructured":"Efron B, Tibshirani RJ (1994) An introduction to the bootstrap: (monographs on statistics and applied probablity). Chapman and Hall, London"},{"key":"5969_CR34","doi-asserted-by":"crossref","first-page":"P372","DOI":"10.1093\/geronb\/63.6.P372","volume":"63","author":"B Goldsworthy","year":"2008","unstructured":"Goldsworthy B, Knowles S (2008) Caregiving for Parkinson\u2019s disease patients: an exploration of a stress-appraisal model for quality of life and burden. J Gerontol B Psychol Sci Soc Sci 63:P372\u2013P376","journal-title":"J Gerontol B Psychol Sci Soc Sci"},{"key":"5969_CR35","first-page":"242","volume":"37","author":"KS Kim","year":"2007","unstructured":"Kim KS, Kim BJ, Kim KH et al (2007) Subjective and objective caregiver burden in Parkinson\u2019s disease. Taehan Kanho Hakhoe Chi 37:242\u2013248","journal-title":"Taehan Kanho Hakhoe Chi"},{"key":"5969_CR36","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1002\/mds.22106","volume":"23","author":"P Martinez-Martin","year":"2008","unstructured":"Martinez-Martin P, Arroyo S, Rojo-Abuin JM, Rodriguez-Blazquez C, Frades B, de Pedro Cuesta J (2008) Burden, perceived health status, and mood among caregivers of Parkinson\u2019s disease patients. Mov Disord 23:1673\u20131680","journal-title":"Mov Disord"},{"key":"5969_CR37","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s11136-004-6253-y","volume":"14","author":"P Martinez-Martin","year":"2005","unstructured":"Martinez-Martin P, Benito-Leon J, Alonso F et al (2005) Quality of life of caregivers in Parkinson\u2019s disease. Qual Life Res 14:463\u2013472","journal-title":"Qual Life Res"},{"key":"5969_CR38","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.parkreldis.2005.06.011","volume":"12","author":"A Schrag","year":"2006","unstructured":"Schrag A, Hovris A, Morley D, Quinn N, Jahanshahi M (2006) Caregiver-burden in Parkinson\u2019s disease is closely associated with psychiatric symptoms, falls, and disability. Parkinsonism Relat Disord 12:35\u201341","journal-title":"Parkinsonism Relat Disord"},{"key":"5969_CR39","doi-asserted-by":"crossref","first-page":"817","DOI":"10.2165\/00019053-200523080-00007","volume":"23","author":"AE Spottke","year":"2005","unstructured":"Spottke AE, Reuter M, Machat O et al (2005) Cost of illness and its predictors for Parkinson\u2019s disease in Germany. Pharmacoeconomics 23:817\u2013836","journal-title":"Pharmacoeconomics"},{"key":"5969_CR40","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s10198-007-0069-y","volume":"9","author":"D Coyle","year":"2008","unstructured":"Coyle D, Oakley J (2008) Estimating the expected value of partial perfect information: a review of methods. Eur J Health Econ 9:251\u2013259","journal-title":"Eur J Health Econ"},{"key":"5969_CR41","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1089\/dis.2006.9.339","volume":"9","author":"K Noyes","year":"2006","unstructured":"Noyes K, Liu H, Temkin-Greener H (2006) Cost of caring for Medicare beneficiaries with Parkinson\u2019s disease: impact of the CMS-HCC risk-adjustment model. Dis Manag 9:339\u2013348","journal-title":"Dis Manag"},{"key":"5969_CR42","doi-asserted-by":"crossref","first-page":"118","DOI":"10.2165\/00019053-199202020-00005","volume":"2","author":"HM Bryson","year":"1992","unstructured":"Bryson HM, Milne RJ, Chrisp P (1992) Selegiline: an appraisal of the basis of its pharmacoeconomic and quality-of-life benefits in Parkinson\u2019s disease. Pharmacoeconomics 2:118\u2013136","journal-title":"Pharmacoeconomics"},{"key":"5969_CR43","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1345\/aph.1G454","volume":"40","author":"J Hudry","year":"2006","unstructured":"Hudry J, Rinne JO, Keranen T, Eckert L, Cochran JM (2006) Cost-utility model of rasagiline in the treatment of advanced Parkinson\u2019s disease in Finland. Ann Pharmacother 40:651\u2013657","journal-title":"Ann Pharmacother"},{"key":"5969_CR44","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2165\/00019053-200321020-00004","volume":"21","author":"M Iskedjian","year":"2003","unstructured":"Iskedjian M, Einarson TR (2003) Cost analysis of ropinirole versus levodopa in the treatment of Parkinson\u2019s disease. Pharmacoeconomics 21:115\u2013127","journal-title":"Pharmacoeconomics"},{"key":"5969_CR45","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1177\/0272989X07301822","volume":"27","author":"K Noyes","year":"2007","unstructured":"Noyes K, Dick AW, Holloway RG (2007) The implications of using US-specific EQ-5D preference weights for cost-effectiveness evaluation. Med Decis Making 27:327\u2013334","journal-title":"Med Decis Making"},{"key":"5969_CR46","doi-asserted-by":"crossref","first-page":"617","DOI":"10.2165\/00019053-200220090-00005","volume":"20","author":"CS Palmer","year":"2002","unstructured":"Palmer CS, Nuijten MJ, Schmier JK, Subedi P, Snyder EH (2002) Cost effectiveness of treatment of Parkinson\u2019s disease with entacapone in the United States. Pharmacoeconomics 20:617\u2013628","journal-title":"Pharmacoeconomics"},{"key":"5969_CR47","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.parkreldis.2004.05.006","volume":"10","author":"PD Charles","year":"2004","unstructured":"Charles PD, Padaliya BB, Newman WJ et al (2004) Deep brain stimulation of the subthalamic nucleus reduces antiparkinsonian medication costs. Parkinsonism Relat Disord 10:475\u2013479","journal-title":"Parkinsonism Relat Disord"},{"key":"5969_CR48","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1002\/mds.10481","volume":"18","author":"E McIntosh","year":"2003","unstructured":"McIntosh E, Gray A, Aziz T (2003) Estimating the costs of surgical innovations: the case for subthalamic nucleus stimulation in the treatment of advanced Parkinson\u2019s disease. Mov Disord 18:993\u2013999","journal-title":"Mov Disord"},{"key":"5969_CR49","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s00415-002-0711-7","volume":"249","author":"EA Spottke","year":"2002","unstructured":"Spottke EA, Volkmann J, Lorenz D et al (2002) Evaluation of healthcare utilization and health status of patients with Parkinson\u2019s disease treated with deep brain stimulation of the subthalamic nucleus. J Neurol 249:759\u2013766","journal-title":"J Neurol"},{"key":"5969_CR50","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1002\/mds.21652","volume":"22","author":"F Valldeoriola","year":"2007","unstructured":"Valldeoriola F, Morsi O, Tolosa E, Rumia J, Marti MJ, Martinez-Martin P (2007) Prospective comparative study on cost-effectiveness of subthalamic stimulation and best medical treatment in advanced Parkinson\u2019s disease. Mov Disord 22:2183\u20132191","journal-title":"Mov Disord"},{"key":"5969_CR51","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1177\/105477389500400404","volume":"4","author":"RA Berry","year":"1995","unstructured":"Berry RA, Murphy JF (1995) Well-being of caregivers of spouses with Parkinson\u2019s disease. Clin Nurs Res 4:373\u2013386","journal-title":"Clin Nurs Res"},{"key":"5969_CR52","unstructured":"Edwards NE, Ruettiger KM (2002) The influence of caregiver burden on patients\u2019 management of Parkinson\u2019s disease: implications for rehabilitation nursing. Rehabil Nurs 27:182\u2013186, 198"},{"issue":"5","key":"5969_CR53","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/ageing\/31.5.349","volume":"31","author":"S Happe","year":"2002","unstructured":"Happe S, Berger K (2002) The association between caregiver burden and sleep disturbances in partners of patients with Parkinson\u2019s disease. Age Ageing 31(5):349\u2013354","journal-title":"Age Ageing"},{"key":"5969_CR54","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.disamonth.2007.02.006","volume":"53","author":"SL Reese","year":"2007","unstructured":"Reese SL (2007) Psychosocial factors in Parkinson\u2019s disease. Dis Mon 53:291\u2013295","journal-title":"Dis Mon"},{"key":"5969_CR55","unstructured":"Teel CS, Press AN (1999) Fatigue among elders in caregiving and noncaregiving roles. West J Nurs Res 21:498\u2013514; discussion 514\u2013420"},{"key":"5969_CR56","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/j.1468-1331.2008.02380.x","volume":"16","author":"C Vossius","year":"2009","unstructured":"Vossius C, Nilsen OB, Larsen JP (2009) Parkinson\u2019s disease and nursing home placement: the economic impact of the need for care. Eur J Neurol 16:194\u2013200","journal-title":"Eur J Neurol"},{"key":"5969_CR57","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1002\/mds.21171","volume":"21","author":"KK Martikainen","year":"2006","unstructured":"Martikainen KK, Luukkaala TH, Marttila RJ (2006) Parkinson\u2019s disease and working capacity. Mov Disord 21:2187\u20132191","journal-title":"Mov Disord"},{"key":"5969_CR58","doi-asserted-by":"crossref","first-page":"240","DOI":"10.5664\/jcsm.27493","volume":"5","author":"P Jennum","year":"2009","unstructured":"Jennum P, Knudsen S, Kjeldberg J (2009) The economic consequences of narcolepsy. J Clin Sleep Med 5:240\u2013245","journal-title":"J Clin Sleep Med"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-011-5969-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-011-5969-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-011-5969-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T07:26:03Z","timestamp":1592378763000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-011-5969-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3,11]]},"references-count":58,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["5969"],"URL":"https:\/\/doi.org\/10.1007\/s00415-011-5969-1","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,3,11]]}}}